The present invention is directed to an ophthalmic formulation which comprises a therapeutically effective amount of ethyl 4-(8-chloro-5,6-dihydro-11-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate, known as loratadine, a fatty acid ester, and a surfactant, which has been found to be useful in treating ocular allergies, especially allergic conjunctivitis, and related conditions.